<DOC>
	<DOCNO>NCT02643147</DOCNO>
	<brief_summary>Worsening renal function ( WRF ) frequent find patient decompensated acute heart failure ( AHF ) associate increased length hospitalization high morbidity mortality . Traditionally , WRF AHF set attribute low cardiac output , recent evidence also suggest venous congestion play crucial role . Loop diuretic mainstay treatment AHF , use traditionally associate WRF , also renal function improvement patient unequivocal sign congestion . Nevertheless , traditional symptom sign patient AHF show limited accuracy neither identify quantify degree venous congestion . Recent author report plasma level antigen carbohydrate 125 ( CA125 ) closely related degree venous congestion . The investigator hypothesize CA125 may role identify hyperhydrated ( High CA125 ) patient need high loop diuretic dos , normal CA125 value need low loop diuretic dos . In randomized study ( 1:1 ) investigator seek evaluate whether CA125 loop diuretic guide management therapy superior standard strategy . The primary endpoint magnitude change renal function 24 72 hour initiation intravenous diuretic acute worsen heart failure</brief_summary>
	<brief_title>Loop Diuretic Dosage Patients With Acute Heart Failure Renal Failure : Conventional Versus Carbohydrate Antigen 125-guided Therapy ( IMPROVE-HF )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>Patients diagnosis acute heart failure ( AHF ) concurrence follow condition : 1 . Presence symptom ( dyspnea rest minimal exertion ) sign attributable congestion ( sign congestion chest radiography , presence peripheral edema ascites , jugular venous distension 45 degree presence crackle auscultation ) . 2 . Elevated natriuretic peptide ( NTproBNP &gt; 1000 pg/ml BNP &gt; 100 mg/dl ) . 3 . Creatinine ≥1,4 mg/dl admission , provide estimate glomerular filtration rate le 60 ml / min / m2 . 4 . Intent treat loop diuretic intravenously . 1 . Life expectancy le 6 month life due comorbid condition . 2 . Cardiogenic shock . 3 . Diagnosis acute coronary syndrome previous 30 day . 4 . Pregnancy time inclusion . 5 . Restrictive Obstructive pulmonary disease severe degree . 6 . Chronic renal insufficiency stage V ( estimate glomerular filtration rate &lt; 15 ml / min / m2 ) patient previously include known dialysis program . 7 . Participation another clinical trial randomize time inclusion . 8 . Temperature ≥38 ° C diagnosis pneumonia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>Biomarker guided-therapy</keyword>
	<keyword>Loop diuretic</keyword>
	<keyword>Carbohydrate antigen 125</keyword>
</DOC>